OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Haematology is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	294
In the trenches	229
Zanubrutinib-associated ecchymotic lesions	215
Prioritising health equity alongside donation safety – Authors' reply	195
Correction to Lancet Haematol 2023; 10: e333–45	164
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	161
Correction to Lancet Haematol 2024; 11: e114–26	138
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	134
Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm	128
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	114
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	113
Managing haematological malignancies in pregnant women	112
MRD-guided treatment cessation in multiple myeloma	108
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	107
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	105
Vaccine efficacy and iron deficiency: an intertwined pair?	94
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	93
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	88
International Society on Thrombosis and Haemostasis Congress 2023	86
Be compliant or compromise?	82
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	82
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	75
Bedside art is good medicine	74
Sequencing therapies in Hodgkin lymphoma	71
Artwork from trauma: the social life of medical data	71

CAR T cells in CNS-relapsed leukaemia: one step forward	69
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	68
Rituximab versus active surveillance in patients with follicular lymphoma	65
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	65
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	65
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	64
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	63
Blood deserts: a vision to tackle blood inaccessibility	63
Living with sickle cell disease: voices from sub-Saharan Africa	61
Blood cell defence against pathogens	60
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	59
Correction to Lancet Haematol 2023; 10: e433–44	59
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	58
Production and supply of blood products in Brazil	58
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	56
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	55
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	55
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	55
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	54
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	52
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	50
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	50
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	50
Sickle cell disease in India: current status and progress	50
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	49
Could improving mental health disorders help increase cancer survival?	49
Universal health coverage for children with cancer	49